$6.56
0[0.00%]
At close: May 22
$6.56
0[0.00%]
PreMarket: 4:00PM EDT
Travere Therapeutics
(NASDAQ:TVTX)Latest News for Travere Therapeutics Stock (NASDAQ:TVTX)
Travere Therapeutics Stock (NASDAQ: TVTX)
Categories: All
Tuesday, May 07, 2024
- HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $19 Price TargetBenzinga Newsdesk - May 7, 2024, 2:10PM
- Expert Outlook: Travere Therapeutics Through The Eyes Of 6 AnalystsBenzinga Insights - May 7, 2024, 2:00PM
- Travere Therapeutics shares are trading higher following Q1 earnings.Benzinga Newsdesk - May 7, 2024, 11:20AM
- Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $18Benzinga Newsdesk - May 7, 2024, 10:20AM
Monday, May 06, 2024
Wednesday, April 24, 2024
- HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $19Benzinga Newsdesk - Apr 24, 2024, 2:38PM
- CSL Vifor And Travere Therapeutics Granted European Commission Conditional Marketing Authorization For FILSPARI (Sparsentan) For The Treatment Of IgA NephropathyBenzinga Newsdesk - Apr 24, 2024, 3:14AM
Friday, April 19, 2024
Wednesday, April 17, 2024
Wednesday, April 03, 2024
Wednesday, March 27, 2024
Wednesday, March 13, 2024
Monday, March 11, 2024
Friday, February 16, 2024
Thursday, February 15, 2024
Wednesday, February 14, 2024
Thursday, January 25, 2024
Thursday, January 18, 2024
Monday, January 08, 2024
- Travere Therapeutics shares are trading higher after the company issued preliminary Q4 and FY23 net product sales from continuing operations guidance. Also, the company said its cash, cash equivalents and marketable securities are expected to support operations into 2028.Benzinga Newsdesk - Jan 8, 2024, 12:59PM
- Travere Therapeutics Ended 2023 With Approximately $567M In Cash, Cash Equivalents, And Marketable Securities Which Is Expected To Support Operations Into 2028Benzinga Newsdesk - Jan 8, 2024, 7:11AM
- Travere Said It Received 459 New Patient Start Forms For Filspari (Sparsentan) In Q4 Of 2023; Preliminary Net Product Sales Of Filspari Totaled $15M For Q4 And $30M Since The Beginning Of Commercial Launch In February 2023.Benzinga Newsdesk - Jan 8, 2024, 7:10AM
- Travere Therapeutics Expects Q4 FY23 Net Product Sales From Continuing Operations To Be Approximately $40M, Approximately $128M For FY23M.Benzinga Newsdesk - Jan 8, 2024, 7:10AM
Thursday, December 21, 2023
Monday, December 18, 2023
Friday, December 15, 2023
Thursday, December 14, 2023
Wednesday, December 06, 2023
Tuesday, December 05, 2023
- Crude Oil Moves Lower; AutoZone Profit Tops ViewsLisa Levin - Dec 5, 2023, 2:27PM
- Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Dec 5, 2023, 1:06PM
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga Insights - Dec 5, 2023, 12:31PM
- What's Going On With Travere Therapeutics Stock?Erica Kollmann - Dec 5, 2023, 12:02PM
- Travere Therapeutics shares are trading higher after the company announced the completion of a successful pre-NDA meeting with the FDA for FILSPARI in IgA nephropathy and provided regulatory updates for both IgAN and FSGS.Benzinga Newsdesk - Dec 5, 2023, 11:40AM
- NIO Reports Q3 Results, Joins Hovnanian Enterprises, Signet Jewelers And Other Big Stocks Moving Higher On TuesdayLisa Levin - Dec 5, 2023, 10:04AM
- Citigroup Upgrades Travere Therapeutics to Buy, Raises Price Target to $10Benzinga Newsdesk - Dec 5, 2023, 7:22AM
- HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $18 Price TargetBenzinga Newsdesk - Dec 5, 2023, 6:28AM
Monday, December 04, 2023
- 12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga Insights - Dec 4, 2023, 4:31PM
- Travere Expects To Have Cash Runway Into 2028Benzinga Newsdesk - Dec 4, 2023, 4:12PM
- Travere Says FDA Communicated Phase 3 DUPLEX Study Results Alone Are Not Sufficient To Support sNDA Submission For An FSGS Indication For Sparsentan; Co. Plans Conducting Addl. Analyses Of FSGS Data And Plans To Re-engage FDA In 2024Benzinga Newsdesk - Dec 4, 2023, 4:11PM
- Travere Plans To Submit sNDA To FDA In Q1 2024 For Conversion Of Existing US Accelerated Approval Of FILSPARI (Sparsentan) In IgAN To Full ApprovalBenzinga Newsdesk - Dec 4, 2023, 4:08PM
- Travere Successful Pre-NDA Meeting For FILSPARI In IgAN; Says There Is Uncertainty Around A Regulatory Path Forward For FSGS; Implements Approximate 20% Workforce ReductionBenzinga Newsdesk - Dec 4, 2023, 4:07PM